Tandem Diabetes Care has received FDA clearance for its Tandem Mobi system as a tubeless automated insulin delivery device cleared for up to seven days of wear. The product uses a new tubeless cartridge and infusion set to convert the current Tandem Mobi pump into a tubeless device intended to simplify diabetes management by minimizing site changes.
The company said the clearance means Tandem Mobi is now approved for both tubeless and tubed insulin infusion options. Tandem expects the system to become commercially available in the U.S. in 2027.
The Commercial Picture
That dual-format positioning is the main strategic point in the clearance. Tandem said the system will be the only technology to let users choose between wear options once it launches, giving it a differentiation angle beyond the tubeless form factor itself.
The comparison in the source material is direct: Insulet's Omnipod automated insulin delivery system offers only a tubeless wear option and cannot be worn for more than 72 hours. Tandem is pairing a tubeless design with a longer stated wear duration, which could help it compete on convenience rather than only on automation features.
Tandem also said the tubeless infusion sets and cartridges will be available exclusively through the pharmacy for customers with pharmacy benefits. That distribution choice suggests the launch will depend not just on device adoption, but on how smoothly Tandem can fit the product into existing pharmacy benefit access channels.




